1,026 results on '"di Grazia, C."'
Search Results
2. sentenza 14 aprile 2004; Giud. Mondini; Paltrinieri e altri (Avv. Di Grazia) c. Soc. Enel (Avv. Grassi, Passeggio, Maione, Cattani)
3. Sezione III civile; sentenza 14 aprile 1976, n. 1323; Pres. Toro, Est. M. Pedroni, P.M. Grimaldi (concl. conf.); Lorenzetti (Avv. Palombi, Di Grazia) c. Sestini (Avv. Camici, Di Puccio). Conferma Trib. Lucca 26 maggio 1971
4. Sezione II civile; sentenza 16 ottobre 1954, n. 3791; Pres. Oggioni P., Est. Torrente, P. M. Pomodoro (concl. conf.); Mungai (Avv. Beltramo, Di Grazia) c. Tambellini (Avv. Virgilio, Baracchini)
5. Sezione II civile; sentenza 11 dicembre 1950, n. 2713; Pres. Piga P., Est. Cataldi, P. M. Pafundi (concl. diff.); Mannelli (Avv. Cantelli, Di Grazia) c. Ferrari (Avv. Battistini, Carnaroli)
6. Sezione II civile; udienza 7 febbraio 1941, n. 381; Pres. Tommasini P., Est. Sotgiu, P. M. Verde (concl. diff.); Domenici (Avv. Di Grazia) c. Maspes (Avv. Annibaldi, La Valle)
7. Udienza 15 luglio 1910; Pres. Pianigiani P. P., Est. Nonnis; Franceschini (Avv. Franceschini, Di Grazia) c. Marsili (Avv. Galardi, Conti)
8. Sezione III. — Udienza del 28 novembre 1876, Pres. Duchoqué, P. P., Est. Gobbi. G. Di Grazia. c. comune di Sirignano (Avv. C. Errico.)
9. Busulfan-fludarabine versus busulfan-cyclophosphamide for allogeneic transplant in acute myeloid leukemia: long term analysis of GITMO AML-R2 trial.
10. Haploidentical bone marrow transplantation for AML in remission after TBF conditioning: a long-term follow-up.
11. Lower blood levels of isavuconazole in critically ill patients compared with other populations: possible need for therapeutic drug monitoring.
12. Total marrow irradiation for second allogeneic hematopoietic stem cell transplantation in patients with advanced acute leukemia
13. Acute graft versus host disease 1976-2020: reduced incidence and predictive factors.
14. Hepatitis B reactivation in HBsAg-negative/HBcAb-positive allogeneic haematopoietic stem cell transplant recipients: risk factors and outcome
15. Triple Combination Therapy With 2 Antivirals and Monoclonal Antibodies for Persistent or Relapsed Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients.
16. Pre-transplant minimal residual disease assessment and transplant-related factors predict the outcome of acute myeloid leukemia patients undergoing allogeneic stem cell transplantation.
17. DLI after haploidentical BMT with post-transplant CY
18. Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes.
19. Outcome of early treatment of SARS-CoV-2 infection in patients with haematological disorders.
20. Unmanipulated haploidentical bone marrow transplantation and post-transplant cyclophosphamide for hematologic malignanices following a myeloablative conditioning: an update
21. DISCONTINUING IMMUNOSUPPRESSIVE THERAPY FOLLOWING AN ALLOGENEIC HEMOPOIETIC STEM CELL TRANSPLANT (HSCT):A CROSS SECTIONAL ANALYSIS OF 799 PATIENTS, 1 YEAR POST TRANSPLANT: PH-P337
22. UNMANIPULATED HAPLOIDENTICAL TRANSPLANTS FOR ACUTE MYELOID LEUKEMIA (AML) AND REFRACTORY ANEMIA WITH EXCESS BLASTS (RAEB): PH-O126
23. PRE-ENGRAFTMENT BLOODSTREAM INFECTIONS IN 489 HAEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: AETIOLOGY, RISK FACTORS AND IMPACT ON MORTALITY.: PH-O023
24. ALLOGENEIC TRANSPLANTS FOR MYELODISPLASTIC SYNDROMES: STRONG REDUCTION OF TRANSPLANT MORTALITY IN RECENT YEARS: PH-O013
25. Extracorporeal photopheresis for the treatment of steroid refractory acute GVHD
26. Assessment of orbital volume and morphological changes after rapid maxillary expansion performed with tooth-bone and bone-borne devices. A retrospective study using surface-to surface matching technique
27. Enhancing the diagnosis of maxillary transverse discrepancy through 3-D technology and surface-to-surface superimposition. Description of the digital workflow with a documented case report
28. Factors predicting response and graft-versus-host disease after donor lymphocyte infusions: a study on 593 infusions
29. Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts: a single Center experience in 488 patients: O383
30. Anti-CD26 monoclonal antibody for the treatment of steroidrefractory acute graft-versus-host disease (SR-GvHD): a report of two prospective studies: O159
31. Allogeneic bone marrow transplantation (BMT) for adults with acute lymphoblastic leukemia (ALL): predictive role of minimal residual disease monitoring on relapse
32. Serum cholinesterase is an early and sensitive marker of graft-versus host-disease (GVHD) and transplant-related mortality (TRM)
33. Pre-emptive therapy of acute graft-versus-host disease: a pilot study with antithymocyte globulin (ATG)
34. Risk factors for non-relapse mortality in 287 patients receiving 1288 donor lymphocyte infusions: P1046
35. Post-transplant CMV reactivation after CBT: the role of delayed immune reconstitution or donorʼs seronegativity?: P756
36. Acute graft-versus-host disease II-IV in 1465 patients: has outcome improved over the past two decades?: O386
37. Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: report from the chronic malignancies working party of EBMT.
38. Predicting the outcome for patients with myelofibrosis undergoing an allogeneic hemopoietic stem cell transplant.
39. Second haploidentical stem cell transplantation for primary graft failure.
40. Thiotepa-based reduced intensity conditioning regimen: a 10 year follow up
41. Successful non-invasive management of late-onset haemorrhagic cystitis in intrabone cord blood transplant recipients
42. Acute disseminated encephalomyelitis after allogenic bone marrow transplantation. Report of two cases
43. Invasive aspergillosis in allogeneic stem cell transplant recipients from alternative donor: incidence, risk factors and outcome
44. Immune reconstitution after cord blood transplantation by direct intrabone injection of cells
45. Allogeneic hemopoietic stem cell transplants for patients with relapsed acute leukemia: long-term outcome
46. Reduction of transplant related mortality with time: major improvement for patients allografted with early disease
47. Myeloablative conditioning with thiotepa-busulfan-fludarabine does not improve the outcome of patients transplanted with active leukemia: final results of the GITMO prospective trial GANDALF-01.
48. The day 100 score predicts moderate to severe cGVHD, transplant mortality, and survival after hematopoietic cell transplantation.
49. Molecular relapse of acute lymphoblastic leukaemia after allogeneic haematopoietic stem cell transplantation can be successfully treated with donor lymphocyte infusions
50. Vincristine as salvage treatment for refractory thrombotic thrombocytopenic purpura
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.